An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Gastrointestinal Cancers


Interview with Axel Grothey, MD

Track 1: Increased incidence of colorectal cancer (CRC) in people younger than age 50
Track 2: Molecular profiling for patients with metastatic CRC (mCRC)
Track 3: Therapeutic options for patients with HER2-amplified mCRC
Track 4: Significance of BRAF mutation status and left or right primary tumor site in therapeutic decision-making for mCRC
Track 5: Clinical experience with the combination of EGFR antibodies and BRAF and MEK inhibitors
Track 6: ReDOS Phase II trial of regorafenib dosing strategies and associated side effects
Track 7: Optimal sequence of TAS-102 and regorafenib for mCRC
Track 8: Role of checkpoint inhibitors in the treatment of mismatch repair-deficient, microsatellite instability (MSI)-high mCRC
Track 9: Response to monotherapy with anti-PD-1/PD-L1 antibodies
Track 10: MSI testing for patients with metastatic solid tumors
Track 11: Biologic rationale for targeting cancer stemness pathways in colorectal and gastric cancer
Track 12: Available clinical trial data on the efficacy of the cancer stemness inhibitor napabucasin in gastric and colorectal cancer
Track 13: Selection and sequencing of therapy, including checkpoint inhibitors, for patients with advanced gastric cancer
Track 14: Novel agents and strategies under investigation for gastric cancer

Interview with Philip A Philip, MD, PhD

Track 1: PRODIGE 24 trial: Adjuvant modified FOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma (PDAC)
Track 2: Role of postoperative radiation therapy in the treatment of PDAC
Track 3: APACT trial: Ongoing Phase III evaluation of gemcitabine with nanoparticle albumin-bound (nab) paclitaxel as adjuvant therapy
Track 4: Neoadjuvant therapy for patients with potentially resectable metastatic PDAC (mPDAC)
Track 5: Nanoliposomal irinotecan and other second-line therapy options for mPDAC
Track 6: Activity and tolerability of nanoliposomal irinotecan/5-FU/LV
Track 7: BRCA mutation testing and efficacy of PARP inhibitors for patients with pancreatic cancer
Track 8: Mechanism of action of cancer stemness inhibitor napabucasin
Track 9: Emerging clinical data with napabucasin in patients with pancreatic cancer
Track 10: First-line treatment options for patients with hepatocellular carcinoma (HCC)
Track 11: Lenvatinib as first-line treatment of HCC
Track 12: Regorafenib, nivolumab and other therapeutic options for HCC in the second-line setting
Track 13: Activity of immune checkpoint inhibitors for HCC
Track 14: Role of tyrosine kinase inhibitors for patients with HCC and compromised liver function
Track 15: Transarterial chemoembolization for patients with HCC
Track 16: Efficacy of the anti-VEGFR antibody ramucirumab for patients with HCC
Track 17: Targeting DNA repair pathways and other novel approaches under investigation for pancreatic cancer
Axel Grothey, MD
Professor of Oncology
West Cancer Center
University of Tennessee
Memphis, Tennessee
Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and
Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Neil Love, MD
Research To Practice
Miami, Florida